Trial Profile

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribitol (Primary)
Indications Limb girdle muscular dystrophies
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms Fortify
Sponsors ML Bio Solutions

Most Recent Events

09 Sep 2026 Planned End Date changed from 1 Jul 2027 to 1 Sep 2027.
09 Sep 2026 Planned primary completion date changed from 1 Jul 2027 to 1 Sep 2027.
10 Aug 2026 According to a BridgeBio Pharma media release, company presented interim data from the phase 3 FORTIFY trial at the 19th International Congress on Neuromuscular Diseases in July 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com